ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

AChR-Ab Seropositive Generalized Myasthenia Gravis
Myasthenia Gravis
MG
gMG
Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG)

Interventions

BIOLOGICAL: Efgartigimod IV
BIOLOGICAL: Empasiprubart IV

Sponsor

argenx